New CAR-T cell therapy aims to keep High-Risk leukemia at bay
NCT ID NCT07053059
Summary
This study is testing whether a personalized cell therapy called obecabtagene autoleucel (obe-cel) can help control a high-risk type of blood cancer (B-cell ALL) when given after the first round of treatment. Researchers will give the therapy to about 30 adults with this specific leukemia to see if it improves survival and keeps the cancer from returning. The main goal is to see if patients remain cancer-free for 18 months after receiving the therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.